{"id":"https://openalex.org/W4310113849","doi":"https://doi.org/10.1182/blood-2022-164757","title":"Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status","display_name":"Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310113849","doi":"https://doi.org/10.1182/blood-2022-164757"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-164757","doi":"https://doi.org/10.1182/blood-2022-164757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-164757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073204184","display_name":"Michael Jamie Hochman","orcid":"https://orcid.org/0000-0003-0594-154X","observed_orcids":["https://orcid.org/0000-0003-0594-154X"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Hochman","raw_affiliation_strings":["1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026586699","display_name":"Alexander Joseph Ambinder","orcid":"https://orcid.org/0000-0003-0855-9653","observed_orcids":["https://orcid.org/0000-0003-0855-9653"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander J. Ambinder","raw_affiliation_strings":["1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064140300","display_name":"Lukasz P. Gondek","orcid":"https://orcid.org/0000-0002-1551-3496","observed_orcids":["https://orcid.org/0000-0002-1551-3496"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lukasz P. Gondek","raw_affiliation_strings":["1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035609080","display_name":"Amy Elizabeth Dezern","orcid":"https://orcid.org/0000-0001-5225-4609","observed_orcids":["https://orcid.org/0000-0001-5225-4609"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy E. DeZern","raw_affiliation_strings":["1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.1823,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.53144016,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"3387","last_page":"3388"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8349999785423279},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9990000128746033},{"id":"https://openalex.org/keywords/intensive-chemotherapy","display_name":"intensive chemotherapy","score":0.949999988079071},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8320000171661377},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8830000162124634},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.8209999799728394},{"id":"https://openalex.org/keywords/hematopoietic-stem-cell-transplantation","display_name":"hematopoietic stem cell transplantation","score":0.7279999852180481},{"id":"https://openalex.org/keywords/multiparameter-flow-cytometry","display_name":"multiparameter flow cytometry","score":0.7020000219345093},{"id":"https://openalex.org/keywords/eln-risk-stratification","display_name":"ELN risk stratification","score":0.5509999990463257},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.37599998712539673},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.7639999985694885},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6039999723434448},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.3580000102519989}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7961866855621338},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6699842214584351},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5771276354789734},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.5605176687240601},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.503131091594696},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.4867558479309082},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4614291191101074},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.4539186954498291},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.4242633581161499},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.4199136793613434},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.40432208776474},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.401841402053833},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32673490047454834},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.13894492387771606},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-164757","doi":"https://doi.org/10.1182/blood-2022-164757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-164757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7204684801","https://openalex.org/W4229070734","https://openalex.org/W4389244534","https://openalex.org/W3216817653","https://openalex.org/W4405042375","https://openalex.org/W4417016708","https://openalex.org/W2985247963","https://openalex.org/W7093121382","https://openalex.org/W3096522497","https://openalex.org/W4402335181"],"abstract_inverted_index":{"Background:":[0],"Intensive":[1],"chemotherapy":[2,209,586],"regimens":[3,44],"(IC;":[4],"e.g.,":[5],"7+3":[6],"or":[7,62,102,151,299,634],"CPX-351)":[8],"broadly":[9],"target":[10],"leukemic":[11,35],"blast":[12],"populations":[13],"in":[14,34,57,94,177,246,264,308,361,416,426,465,478,531,568,582,598,650],"acute":[15],"myeloid":[16],"leukemia":[17],"(AML)":[18],"by":[19,106,160,217,595,606],"interfering":[20],"with":[21,74,128,164,301,388,418,437,445,584,632],"DNA":[22],"replication,":[23],"whereas":[24,458],"hypomethylating":[25],"agent/venetoclax":[26],"therapy":[27,275,544,556,573],"(HMA/ven)":[28],"takes":[29],"advantage":[30],"of":[31,40,173,197,313,344,414,512,570,627,648],"metabolic":[32],"vulnerabilities":[33],"stem":[36,204],"cells":[37],"via":[38],"inhibition":[39],"anti-apoptotic":[41],"pathways.":[42],"IC":[43,315,342,366,379],"are":[45,60,103,630,641],"often":[46],"targeted":[47],"to":[48,89,200,239,248,383,443,501,591,643],"'fit',":[49],"younger":[50,400],"patients,":[51],"while":[52],"HMA/ven":[53,198,334,393,472],"is":[54],"typically":[55],"used":[56,238],"patients":[58,96,125,291,316,330,335,364,370,417,436,518,583],"who":[59,63,374],"older":[61,338],"have":[64],"significant":[65,84,463,563],"comorbidities.":[66],"Both":[67],"therapeutic":[68],"paradigms":[69],"can":[70],"induce":[71],"morphologic":[72],"remission,":[73],"resultant":[75],"measurable":[76],"residual":[77],"disease":[78,167],"(MRD)":[79],"status":[80,101,180,216,346,391,425,560,597,603],"remaining":[81],"a":[82,297,325,549],"prognostically":[83],"factor.":[85],"Here,":[86],"we":[87],"aim":[88],"determine":[90,645],"whether":[91,628],"post-remission":[92],"outcomes":[93,489,581],"AML":[95,129,651],"depend":[97],"mainly":[98],"on":[99,118],"MRD":[100,215,278,345,355,390,446,559,571,596,602,649],"further":[104,309],"modified":[105],"chosen":[107],"induction":[108,654],"(IC":[109,211],"vs":[110,186,212,350,395,404],"HMA/ven).":[111],"Methods:":[112],"Retrospective":[113],"chart":[114],"review":[115],"was":[116,158,359,460,561],"performed":[117,282],"adult":[119],"(age":[120],"18":[121],"years":[122],"and":[123,130,141,168,214,230,258,277,305,322,367,398,429,483,528,546,558],"older)":[124],"newly":[126],"diagnosed":[127],"treated":[131],"at":[132],"Johns":[133],"Hopkins":[134],"Hospital,":[135],"Baltimore,":[136],"MD":[137],"between":[138,256,468,555,572],"September":[139],"2014":[140],"June":[142],"2021.":[143],"Patients":[144,373,477],"were":[145,223,237,262,281,306,336,380,399],"excluded":[146],"if":[147],"they":[148],"had":[149,440,487,498],"promyelocytic":[150],"mixed":[152],"phenotype":[153],"leukemia.":[154],"Complete":[155],"remission":[156,358],"(CR)":[157],"defined":[159],"<5%":[161],"medullary":[162],"blasts":[163],"no":[165,461,566],"extramedullary":[166],"count":[169,303],"recovery.":[170],"Primary":[171],"covariates":[172,261],"interest":[174],"included":[175,270,307],"age":[176,348,402],"years,":[178,352,406],"performance":[179],"(PS;":[181],"ECOG":[182],"0-1":[183],"for":[184,188,274,494,514,541,613],"good":[185],"2-4":[187],"poor),":[189],"European":[190],"LeukemiaNet":[191],"(ELN)":[192],"2022":[193,421],"risk":[194,422,517],"group,":[195],"number":[196],"cycles":[199],"best":[201],"response,":[202],"hematopoietic":[203],"cell":[205],"transplantation":[206],"(HCT)":[207],"status,":[208],"type":[210,276,557,587],"HMA/ven),":[213],"multiparametric":[218],"flow":[219],"cytometry":[220],"(MFC).":[221],"Groups":[222],"compared":[224],"using":[225,251,283],"Wilcoxon":[226],"rank":[227],"sum,":[228],"Kruskal-Wallis,":[229],"Fisher's":[231],"exact":[232],"tests.":[233],"Laplace":[234],"regression":[235],"models":[236],"estimate":[240],"subgroup":[241],"median":[242,466],"overall":[243],"survivals":[244],"(OS)":[245],"order":[247],"compare":[249],"them":[250],"the":[252,259,289,479,646],"Wald":[253],"test.":[254],"Associations":[255],"OS":[257,451,467,491],"above":[260],"examined":[263],"Cox":[265],"models;":[266],"one":[267],"multivariable":[268],"model":[269],"an":[271,552],"interaction":[272,553],"term":[273,554],"status.":[279],"Analyses":[280],"Stata":[284],"version":[285],"17.":[286],"Results:":[287],"Of":[288],"388":[290],"initially":[292],"reviewed,":[293],"214":[294],"(55%)":[295],"achieved":[296,360,375,631],"CR":[298,300,533],"incomplete":[302],"recovery":[304],"analysis.":[310],"Most":[311],"(103":[312],"159)":[314],"received":[317,320,324,331],"7+3;":[318],"20":[319],"CPX-351":[321],"36":[323],"high-dose":[326],"cytarabine-based":[327],"regimen.":[328],"Fifty-five":[329],"HMA/ven.":[332,372],"The":[333],"significantly":[337,411,608],"than":[339,386],"those":[340,387,444,529,599],"receiving":[341],"regardless":[343,626],"(median":[347,401,450,490],"72":[349],"58":[351],"respectively,":[353],"P<0.001).":[354,407],"negative":[356],"(MRD-)":[357],"134":[362],"(84.3%)":[363],"after":[365,371,378,392,539,652],"44":[368],"(80.0%)":[369],"MRD-":[376,424,438,481,485,530,623],"CRs":[377],"more":[381],"likely":[382],"undergo":[384],"HCT":[385,430],"identical":[389],"(77.6%":[394],"40.9%,":[396],"P<0.001)":[397],"60":[403],"73":[405],"Univariate":[408],"analysis":[409,508],"showed":[410,435,509],"decreased":[412,510],"hazard":[413],"death":[415,513],"favorable":[419,516],"ELN":[420,515],"score,":[423],"first":[427,532],"CR,":[428],"(Table":[431],"1).":[432,506],"Kaplan-Meier":[433],"curves":[434],"remissions":[439,449,624],"superior":[441,499],"survival":[442,500,594,610],"positive":[447],"(MRD+)":[448],"not":[452,492,562,589],"reached":[453,493],"vs.":[454,473],"21.9":[455],"months,":[456],"P<0.05),":[457],"there":[459],"statistically":[462],"difference":[464,567],"therapies":[469],"(36.1":[470],"months":[471,475],"61.2":[474],"IC).":[476],"IC,":[480],"group":[482,486],"HMA/ven,":[484],"similar":[488],"both);":[495],"both":[496],"groups":[497,503],"MRD+":[502],"(P<0.05;":[504],"Figure":[505,656],"Multivariable":[507],"hazards":[511],"(hazard":[519],"ratio":[520],"[HR]":[521],"0.49,":[522],"95%":[523,536],"confidence":[524],"interval":[525],"[CI]":[526],"0.28-0.85)":[527],"(HR":[534],"0.47,":[535],"CI":[537],"0.28-0.77)":[538],"adjusting":[540,612],"age,":[542],"PS,":[543],"type,":[545],"cycles.":[547],"In":[548,576],"subsequent":[550],"model,":[551],"(HR=0.96,":[564],"suggesting":[565],"impact":[569,593],"types).":[574],"Conclusions:":[575],"this":[577],"retrospective":[578],"study":[579],"evaluating":[580],"AML,":[585],"does":[588],"appear":[590],"differentially":[592],"achieving":[600],"remission.":[601],"as":[604],"measured":[605],"MFC":[607],"impacts":[609],"when":[611],"relevant":[614],"baseline":[615],"covariates.":[616],"These":[617],"results":[618],"suggest":[619],"that":[620],"obtaining":[621],"deep,":[622],"matters":[625],"these":[629],"HMA/venetoclax":[633],"intensive":[635],"therapy.":[636],"Ultimately,":[637],"randomized":[638],"controlled":[639],"trials":[640],"needed":[642],"better":[644],"value":[647],"different":[653],"strategies.":[655],"1View":[657,660],"largeDownload":[658,661],"PPTFigure":[659],"PPT":[662],"Close":[663],"modal":[664]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-11-30T00:00:00"}